These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 36472139)

  • 1. Evaluating the impact of early vs delayed ofatumumab initiation and estimating the long-term outcomes of ofatumumab vs teriflunomide in relapsing multiple sclerosis patients in Spain.
    Vudumula U; Patidar M; Gudala K; Karpf E; Adlard N
    J Med Econ; 2023; 26(1):11-18. PubMed ID: 36472139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup Analyses.
    Williams MJ; Amezcua L; Cohan SL; Cohen JA; Delgado SR; Hua LH; Lucassen EB; Piccolo RS; Koulouris CR; Stankiewicz J
    Neurology; 2024 Aug; 103(3):e209610. PubMed ID: 39018512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.
    Gärtner J; Hauser SL; Bar-Or A; Montalban X; Cohen JA; Cross AH; Deiva K; Ganjgahi H; Häring DA; Li B; Pingili R; Ramanathan K; Su W; Willi R; Kieseier B; Kappos L
    Mult Scler; 2022 Sep; 28(10):1562-1575. PubMed ID: 35266417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
    Kappos L; Fox RJ; Burcklen M; Freedman MS; Havrdová EK; Hennessy B; Hohlfeld R; Lublin F; Montalban X; Pozzilli C; Scherz T; D'Ambrosio D; Linscheid P; Vaclavkova A; Pirozek-Lawniczek M; Kracker H; Sprenger T
    JAMA Neurol; 2021 May; 78(5):558-567. PubMed ID: 33779698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis.
    Berkovich R; Negroski D; Wynn D; Sellers D; Bzdek KG; Lublin AL; Rawlings AM; Quach C; Wells DP; Dumlao M; Bora A; Ranno AE; Luo KL; Chavin J; Hua LH; Becker D
    Mult Scler Relat Disord; 2023 Feb; 70():104472. PubMed ID: 36566698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. To wait, or too late? Modeling the effects of delayed ofatumumab treatment in relapsing-remitting multiple sclerosis.
    Montgomery SM; Green L; Karoui H; Nicholas R; Loh J
    J Med Econ; 2023; 26(1):139-148. PubMed ID: 36546701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension.
    Hauser SL; Zielman R; Das Gupta A; Xi J; Stoneman D; Karlsson G; Robertson D; Cohen JA; Kappos L
    Mult Scler; 2023 Oct; 29(11-12):1452-1464. PubMed ID: 37691530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
    Soini E; Joutseno J; Sumelahti ML
    Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada.
    Bhan V; Clift F; Baharnoori M; Thomas K; Patel BP; Blanchette F; Adlard N; Vudumula U; Gudala K; Dutta N; Grima D; Mouallif S; Farhane F
    J Comp Eff Res; 2023 Sep; 12(9):e220175. PubMed ID: 37606897
    [No Abstract]   [Full Text] [Related]  

  • 10. The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment.
    Hauser SL; Kappos L; Bar-Or A; Wiendl H; Paling D; Williams M; Gold R; Chan A; Milo R; Das Gupta A; Karlsson G; Sullivan R; Graham G; Merschhemke M; Häring DA; Vermersch P
    Neurol Ther; 2023 Oct; 12(5):1491-1515. PubMed ID: 37450172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials.
    Ziemssen T; Arnold DL; Alvarez E; Cross AH; Willi R; Li B; Kukkaro P; Kropshofer H; Ramanathan K; Merschhemke M; Kieseier B; Su W; Häring DA; Hauser SL; Kappos L; Kuhle J
    Front Immunol; 2022; 13():852563. PubMed ID: 35432382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ofatumumab versus Teriflunomide in Multiple Sclerosis.
    Hauser SL; Bar-Or A; Cohen JA; Comi G; Correale J; Coyle PK; Cross AH; de Seze J; Leppert D; Montalban X; Selmaj K; Wiendl H; Kerloeguen C; Willi R; Li B; Kakarieka A; Tomic D; Goodyear A; Pingili R; Häring DA; Ramanathan K; Merschhemke M; Kappos L;
    N Engl J Med; 2020 Aug; 383(6):546-557. PubMed ID: 32757523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in China.
    Xu Y; Mao N; Chirikov V; Du F; Yeh YC; Liu L; Liu R; Gao X
    Clin Drug Investig; 2019 Mar; 39(3):331-340. PubMed ID: 30684251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Confavreux C; O'Connor P; Comi G; Freedman MS; Miller AE; Olsson TP; Wolinsky JS; Bagulho T; Delhay JL; Dukovic D; Truffinet P; Kappos L;
    Lancet Neurol; 2014 Mar; 13(3):247-56. PubMed ID: 24461574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility analysis of teriflunomide in naïve vs. previously treated patients with relapsing-remitting multiple sclerosis in Italy.
    Lazzaro C; Bergamaschi R; Zaffaroni M; Totaro R; Paolicelli D
    Neurol Sci; 2022 Aug; 43(8):4933-4944. PubMed ID: 35420360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
    Hauser SL; Cross AH; Winthrop K; Wiendl H; Nicholas J; Meuth SG; Giacomini PS; Saccà F; Mancione L; Zielman R; Bagger M; Das Gupta A; Häring DA; Jehl V; Kieseier BC; Pingili R; Stoneman D; Su W; Willi R; Kappos L
    Mult Scler; 2022 Sep; 28(10):1576-1590. PubMed ID: 35229668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study.
    Zhang Y; Yin H; Zhang D; Xu Y; Peng B; Cui L
    J Neurol; 2022 Sep; 269(9):4808-4816. PubMed ID: 35403875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis.
    Samjoo IA; Klotz L; Giovannoni G; Drudge C; Haltner A; Worthington E; Zhao M; Brennan R; Häring DA; Cameron C; Adlard N
    Mult Scler Relat Disord; 2022 Oct; 66():104031. PubMed ID: 35841716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.